Gene and Cell Therapies Targeting CNS Disorders Market , By Products-
Gene and Cell Therapies Targeting CNS Disorders Market, By Indications-
Gene and Cell Therapies Targeting CNS Disorders Market , By Region-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Gene and Cell Therapies Targeting CNS Disorders Market Snapshot
Chapter 4. Global Gene and Cell Therapies Targeting CNS Disorders Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
4.9. Clinical Trial/Pipeline Analysis
Chapter 5. Market Segmentation 2: By Products Estimates & Trend Analysis
5.1. By Products & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:
5.2.1. Gene Therapy
5.2.2. Cell Therapy
Chapter 6. Market Segmentation 3: By Indications Estimates & Trend Analysis
6.1. By Indications & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Indications:
6.2.1. Amyotrophic Lateral Sclerosis
6.2.2. Multiple sclerosis
6.2.3. Spinal Cord Injury
6.2.4. Alzehimer
6.2.5. Parkinson Disease
6.2.6. Huntington
6.2.7. Othe Indications
Chapter 7. Gene and Cell Therapies Targeting CNS Disorders Market Segmentation 4: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) estimates and forecasts By Products, 2021-2034
7.1.2. North America Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) estimates and forecasts By Indications, 2021-2034
7.1.3. North America Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Products, 2021-2034
7.2.2. Europe Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Indications, 2021-2034
7.2.3. Europe Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Products, 2021-2034
7.3.2. Asia Pacific Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Indications, 2021-2034
7.3.3. Asia Pacific Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) by country, 2021-2034
7.4. Latin America
7.4.1. Latin America Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Products, 2021-2034
7.4.2. Latin America Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Indications, 2021-2034
7.4.3. Latin America Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) by country, 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Products, 2021-2034
7.5.2. Middle East & Africa Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Indications, 2021-2034
7.5.3. Middle East & Africa Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) by country, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Novartis
8.2.2. BrainStorm Cell Therapeutics
8.2.3. Helixmith
8.2.4. Corestem
8.2.5. Q therapeutics
8.2.6. Helixmith
8.2.7. Rapa Therapeutics
8.2.8. BrainStorm Cell Therapeutics
8.2.9. Neuroplast
8.2.10. StemCyte
8.2.11. Ferrer Internacional
8.2.12. Neuralstem
8.2.13. Ferrer Internacional
8.2.14. Stemedica Cell Technologies
8.2.15. Libella Gene Therapeutics
8.2.16. Sangamo Therapeutics
8.2.17. Hoffmann-La Roche
8.2.18. Longeveron
8.2.19. Sio Gene Therapies
8.2.20. Prevail Therapeutics (Eli Lilly and Company)
8.2.21. NeuroGeneration
8.2.22. Brain Neurotherapy Bio (AskBio)
8.2.23. UniQure Biopharma
8.2.24. Neurogene Inc.
8.2.25. Passage Bio
8.2.26. AXOVANT SCIENCES GMBH
8.2.27. MeiraGTx Limited
8.2.28. Asklepios BioPharmaceutical (AskBio)
8.2.29. Biogen
8.2.30. Sarepta Therapeutics
8.2.31. REGENXBIO Inc.
8.2.32. Lysogene
8.2.33. Voyager Therapeutics
8.2.34. PTC Therapeutics
8.2.35. Other Prominent Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.